Abstract Circulating melanoma cells (CMCs) are thought to be the foundation for metastatic disease, which makes this cancer especially lethal. Cancer cells contained in the primary tumor undergo genotypic and phenotypic changes leading to an epithelial-to-mesenchymal transition, during which numerous changes occur in signaling pathways and proteins in the cells. CMCs are then shed off or migrate from the primary tumor and intravasate the vasculature system. A few CMCs are able to survive in the circulation through expression of a variety of genes and also by evading immune system recognition to establish metastases at distant sites after extravasating from the vessels. The presence of CMCs in the blood of a melanoma patient can be used for disease staging, predicting metastasis development, and evaluating the efficacy of therapeutic agents. Overall survival and disease-free duration can also be correlated with the presence of CMCs. Finally, analysis of CMCs for druggable therapeutic gene targets could lead to the development of personalized treatment regimens to prevent metastasis. Thus, the study of CMCs shows promise for the detection, staging, and monitoring of disease treatment, as well as for determination of prognosis and predicting overall disease-free survival. These are the areas reviewed in this article.
Introduction
Circulating melanoma cells (CMCs) are cancerous melanocytes that dissociate from the primary tumor and circulate through the bloodstream, forming the basis of metastatic disease [1, 2] . CMCs lose epithelial junctions and break off from solid tumors. Cells with high metastatic potential enter the bloodstream or intravasate vessels and circulate in the vasculature to reach tissue areas that are fit for metastasis development [3] . In order to establish metastatic tumors, extravasation (or movement out of the vessels)-which can be facilitated by interactions with neutrophils or other immune cells [4] -must occur, enabling the cells to invade susceptible tissues [3] . The study of CMCs shows much promise in the detection, staging, and monitoring of disease treatment, as well as determination of prognosis and predicting overall diseasefree survival [5] . These are the areas focused on in this review.
HGF (epithelial, fibroblast, and hepatocyte growth factors) via intracellular transduction pathways [1, [9] [10] [11] . Additionally, changes occur in the MAPK pathway and the increased expression of SNA1 (Snail and twist), Wnt, Notch, SPARC, and Hedgehog [12] [13] [14] [15] [16] . Early-stage melanocytic lesion cells cease expression of CDH1 and begin expressing CDH5/non-epithelial cadherin, a calciumdependent adhesion molecule, which binds the cells less tightly than does the normally expressed epithelial cadherin [1, [9] [10] [11] 17] . The expression of CDH5 leads to the loss of characteristic epithelial intercellular adhesion by reduction of gap junctions, desmosomes, and other adhesion molecules [3, 11, 18] .
As a consequence of the EMT, melanocytic lesion cells take on characteristics of motile mesenchymal progenitor cells [19] , allowing for movement and dermal invasion [3, 20] . Dermal invasion is stimulated by the increased activity of Wnt5a and the activation of PKC, causing cytoskeletal changes that enhance cell motility [21] . Melanocytic lesion cells are attracted to the lymph or blood vessels by macrophage-mediated secretion of cytokines, chemokines, and growth factors [22] . The cells then invade, or intravasate, the lymph system or bloodstream ( Fig. 1 ) through passive or active processes. Passive intravasation requires little expenditure of energy, as the invading melanoma cell is sloughed off from the tumor because of increased blood flow and/or low levels of CDH1 [23] . Actively induced intravasation occurs-for example, when melanoma metastatic proteins NEDD9 and DOC-3 are expressed by the cell, leading to the activation of Rac18, causing changes in the actin assembly within the cell, promoting migration into vessels [23] . Other proteins can also be involved in this process. Intravasation through active means can confer better metastatic ability, as the cells are more likely to survive in the bloodstream (Fig. 1) .
Although 4 9 10 6 CMCs can be shed from primary tumors daily (roughly 1 million per gram of tumor tissue), only 1-3, at best, have long term viability in the circulation [1, 24, 25] . Most cells undergo necrosis or apoptosis as a result of the shear stress occurring in the bloodstream or from starvation or immune system intervention [26, 27] . Certain metastasizing cells are resistant to apoptosis because of the deregulation of the PI3K/Akt pathway, which interferes with the regulation of apoptotic genes [28] . Specifically, increases in the phosphorylation of Akt3 and PRAS40 have been associated with progression of melanoma and resistance to apoptosis [29, 30] . Inhibition of either Akt3 or PRAS40 resulted in increased tumor cell apoptosis and susceptibility to apoptosis-inducing drugs [29, 30] . Also contributing to the PI3K/Akt pathway deregulation is phosphatase and tensin homologue (PTEN), a tumor suppressor gene [29, 31] . The loss of PTEN functioning in tumor cells allows for the deregulation of genes within the PI3K/Akt pathway, leading to tumor progression. The introduction of functional PTEN into melanoma cells can inhibit tumor formation by increasing susceptibility to apoptosis [31] . Many other proteins or signaling pathways are also utilized in the evasion of apoptosis by CMCs, including a decrease in the expression of death receptors, increased expression of metalloproteins, increased secretion of growth factors, and overexpression of anti-apoptotic proteins, such as BCL-2, BCL-XL, and FAK (focal adhesion kinase) [28, 32, 33] . In addition, CMCs can avoid detection by natural killer cells, which Fig. 1 Path of a metastasizing melanoma cell, from separation from the primary tumor through the establishment of a metastatic tumor from circulating melanoma cells (CMCs) induce apoptosis by targeting the NKG2D ligand expressed on the surface of certain cells. CMCs internalize the NKGD2 natural killer cell target ligand in order to evade damage from natural killer cells [34] .
Those cells that are able to defy the body's natural defense systems can be the most actively dividing and fit CMCs [35] . These cells are able to survive in the circulatory system and may aggregate to form microemboli or clumps of metastatic cells protected by a collection of surrounding platelets and/ or leukocytes [1, 36, 37] (Fig. 1) . Because of the sheer size of microemboli, they can become entrapped in small capillaries, and CMCs within the mix subsequentially invade susceptible tissue to establish metastases [34, 38] .
Prior to invasion into tissues, extravasation of single CMCs from the vascular system must occur (Fig. 1) . Often, single CMCs capable of metastasis secrete interleukin-8 (IL-8) to facilitate extravasation (Fig. 2) . IL-8 attracts tethering neutrophils to the melanoma cells and, through interaction of intercellular adhesion molecule (ICAM)-1 receptors on melanoma cells and b 2 integrins on neutrophils, the two cells become physically connected [4] . Similar interactions occur between the neutrophil-melanoma complex and the endothelial cells lining the vessels through binding of Sialyl-Lewis tetrasaccharide carbohydrate on the membrane of neutrophils and E-selectin on the surface of the endothelial cell. This results in tethering of the melanoma cells to the endothelial cell, thereby anchoring the CMC in place, which enables growth or invasion of the surrounding tissue, subsequently leading to metastatic tumor establishment ( Fig. 2) [4] .
Vascular development, or angiogenesis, is necessary for the continued expansion in the size of a tumor, and it is this process that might free certain CMCs through passive means. The expression of vascular endothelial growth factor (VEGF) and hypoxia-inducing factor (HIF)-1a induce angiogenesis for the maintenance of cells within tumors [39] . Proper local vascular patterns and tumor cellmicroenvironment interactions can enhance the fitness of a region for CMC invasion and tumor growth [5] .
The cellular markers for CMC identification are similar to those of tumor cells, which include a high nuclear to cytoplasmic ratio [40, 41] and visible nucleoli [40] . In addition, as occurs with the clonal nature of tumors, CMCs show great heterogeneity in ligands expressed on the cell surface and proteins within the cells themselves [42] . This high level of diversity creates a major obstacle in identifying those cells to target in order to inhibit the development of metastatic lesions, and will be an important area of research in the future.
Detection of CMCs
The rarity of CMCs in the bloodstream (1-3 CMCs/*5 billion blood cells) and the lack of current technology to isolate every CMC will require further technological advancements for the field to reach its full potential [1] . A very small number of CMCs-roughly 1-3 cells-can be found in 5 billion blood cells and, as such, very specific and stringent means of detection are necessary to isolate CMCs [1] . Furthermore, CMCs can acquire new genetic mutations from the tumor of origin and are prone to phenotypic drift, which contributes to cellular heterogeneity [35, [43] [44] [45] [46] and accounts for the high variation among markers expressed by these cells. Few specific ligands linked to CMC survival have been identified, and fewer still have been exclusively linked to CMC metastasis [40] . Heterogeneity of cell surface markers complicates the isolation of all CMCs, as capture technology would have to utilize a large variety of markers with high specificity to isolate all cells. Unfortunately, the majority of methods currently available lack the specificity to isolate an accurate number of CMCs or those CMCs specifically leading to metastasis development [47] . Separation of CMCs from red blood cells is rather simple, as red blood cells can be lysed [48] . However, distinguishing CMCs from leukocytes or stray normal epithelial cells is more complex, as many of these cells are caught by CMC-detecting beads and chips or adhere to the entrapped CMCs [5] . Leukocytes are difficult to lyse without affecting CMC survival or capture, and cannot be separated via centrifugation, filtration, or other current technologies [49] . Specific selection for leukocytes via immunocapture using leukocyte surface ligands such as CD45 (negative selection) [48] , or immunocapture using CMC-specific ligands such as Melan-A/MART-1 or MAGE-3 (positive selection) [50] , can be used as a means of separating metastatic cells from leukocytes. However, even using these approaches, it is impossible to eliminate all of the leukocytes.
In recent years, many advances have been made in the development of CMC isolation technologies (Table 1) . Most approaches utilize antibody-coated immunomagnetic beads or microchips to screen for multiple markers, including Melan-A/MART-1, tyrosine, gp100, CD146, and MAGE-3, to account for variability among CMCs [16, 50] . Analysis methods frequently utilize real-time polymerase chain reaction (PCR) analysis, combined with fluorescent imaging selection or immunocytochemistry to identify CMCs or targets indicative of metastatic disease [5, 51, 52] . Associated with these advances are increasing specificity and higher CMC yield during collection, as well as identification and utilization of new markers for CMC isolation. Cells isolated using these approaches are then used for prognostic as well as diagnostic purposes [5] .
Functions of CMCs
CMCs have potential for pinpointing patients who are prone to metastasis and for monitoring the progression of disease, as well as the efficacy of therapies [53] . Detection of CMCs can indicate impending micrometastases prior to clinically observable metastatic tumor formation [54] .
Specifically, they can identify those patients who are prone to relapse after surgical removal of primary tumors [34] . In these patients, CMCs can be symptomatic of the presence of minimally residual disease before currently available clinical measures are able to detect tumor formation [55, 56] . In early-stage patients (stages 0-I), the observation of CMCs can indicate a predisposition to develop distant metastatic tumors as the disease progresses [54] . In one report, two thirds of patients who developed metastases or locally recurrent disease were identified as having CMCs in peripheral blood during the early stages of melanoma [57] .
Since CMCs are necessary, but not indicate metastasis development, CMCs have been used to stage melanoma [50] . However, the specificity and accuracy of the tools used for detection and the intermittent shedding of cells from tumors reduce the reliability of CMCs for melanoma staging, as falsely negative results might not indicate that metastasis has not or will not occur [58] . Despite the controversial results concerning CMC use in cancer diagnosis and prognosis, the majority of studies utilizing realtime PCR for CMC detection have indicated a strong correlation between the number of cells isolated from patient blood samples and the disease stage [52, 59, 60] . Furthermore, the number of patients with detectable numbers of CMCs was lower in stage III disease (observed: 30 %; expected: 60-70 %) and stage IV disease (observed: 45 %; expected: 100 %) than was expected [58] . However, an increase in the number of patients with CMCs has been observed as the stage of disease increases [58] .
There is also controversy over the reliability of CMCs in gauging prognosis for overall survival time, disease-free survival, and the efficacy of targeted therapies. This lack of consensus stems from inconsistency related to the approaches used to capture and analyze these cells [61] . There is no universally accepted method for the collection (i.e. immunomagnetic beads, CTC Chip, CellSearch, etc.), analysis (i.e. real-time PCR, immunocytochemistry, etc.), sensitivity, or specificity of different collection methods. This causes discordant results stemming from variance among the protocols used in different studies. In addition, a plethora of markers (tyrosine, Melan-A/Mart-1, gp100, MAGE-3, EpCAM) are used as identifiers for CMCs, with only cells containing those surface markers being isolated [61] . In some studies, multiple markers have been used in detection of CMCs; however, in others, only one marker such as EpCAM was used, which eliminated collection of those cells lacking this marker [59] . The propensity for accurate identification and isolation of CMCs depends entirely upon the markers that are used. Therefore, antibodies common to normal cells can result in falsely positive detection caused by the capture of epithelial cells or leukocytes [50, 61] . Similarly, falsely negative conclusions can result from using non-specific antibodies or inefficient capture methods [5] . Finally, variations in age and disease stage, sample size, or the number of or time of collection of blood samples used for each patient could result in discordant results [59, 61] . Pretreatment CMC status strongly correlates with overall survival and disease-free survival [47, [62] [63] [64] . In multiple studies, including meta-analyses, CMCs have been found to be relatively accurate gauges of prognosis for survival time [52, 65] . In the Mocellin study in 2004, the presence of CMCs in recently post-operative patients (within 12 months of surgical removal of solid tumors) reliably identified 83 % of melanoma patients who were afflicted by minimally residual disease and relapsed within 8 months of the detection of CMCs [61] . In addition, CMCs were found to be accurate predictors of overall survival [52] . Metastatic melanoma patients who had \2 CMCs in 7.5 mL blood averaged an overall survival time of 12.1 months, whereas those measured as having C2 CMCs had an average decreased overall survival time of 2.0 months [52] .
CMCs in Personalized Therapy
Personalized therapy involves screening for a combination or set of genetic or proteomic changes, which can be associated with increased efficacy of particular chemotherapy or radiotherapy. Efficacy is based on the deregulated proteins expressed or genetic alterations occurring in the tumor of the patient. The specific drugs that are used are based on the cancer targets or deregulated genes in the tumor cells or CMCs isolated from the patient (Fig. 3) [66] . Thus, those drugs are usually designed specifically for the patient receiving the therapy.
Currently, the avenues for personalized therapy are frequently based upon analyses of biopsies of primary tumors; however, in the future, this assessment may be based only on CMCs isolated from patient blood [66] . A continued limitation of the current approach is based on the heterogeneity of tumor cells, which hampers the design of effective personalized therapeutic regimens [42] . A further complication could be that cells contained in a solid tumor grow and proliferate under different conditions than do CMCs or cells undergoing the first steps of metastasis [43] . Tumor cells can be limited by the microenvironment in terms of space or available growth factors for proliferation [43] . Furthermore, prior to undergoing the EMT, tumor cells are tightly packed Fig. 3 Idealized design of targeted personalized therapeutic regimen based on isolation of only metastasizing circulating melanoma cells (CMCs) and selection of therapies against targets in these cells and intercellularly bound, whereas CMCs and those with metastatic potential circulate through the blood individually or in small microemboli (Fig. 1) . CMCs, therefore, exist with fewer spacial restrictions on growth and proliferation. Drugs that target cells in the primary tumor might not affect CMCs or metastatic cells, as they may have lost epithelial ligands, such as those involved in the formation of cell adhesions, during the EMT [6, 7, 42] .
Once isolated, the analysis of expressed surface ligands or deregulated intracellular proteins could be used for the development of personalized treatment. This approach would integrate therapies to specifically target CMCs directly controlling metastasis development. The involvement of CMCs in the design of targeted therapies to inhibit metastasis development is outlined in Fig. 3 . However, a complication of this approach is the heterogeneity of expressed markers in CMCs and the aforementioned differences between these cells and those bound in tumors. This problem could cast doubt on a drug's efficacy for killing both CMCs and tumor-bound cells [47] . As such, information obtained from both biopsies of solid tumors and analysis of CMCs might be the best approach to eliminate these concerns when designing personalized therapies.
The role of CMCs in monitoring the effects of targeted therapy has also been a subject of much controversy. Many studies investigating the change in the number of CMCs isolated from patient blood samples and the success of targeted therapies in treating patients' disease have resulted in inconsistent conclusions [47, 55] . These discrepancies likely stem from the aforementioned lack of a standardized isolation method, an approach for analysis of CMCs, variation in the stages of disease of the test groups, and the frequency of collection of blood samples [61] .
The isolation of CMCs resistant to drugs is a noninvasive approach for early detection of drug resistance [67, 68] . Genetic mutations conferring drug resistance would be predicted in the population of CMCs within the bloodstream. These CMCs would likely be the most fit, resilient, potentially drug-resistant cancer cells in a patient [69] [70] [71] . The separation and analysis of these drug-resistant CMCs could reveal novel mutations, indicating the impending doom of a treatment regimen. If this strategy was successful, it might be a significant advance for cancer treatment and prevention of recurrent resistant disease [53] .
Potential of CMCs for the Prevention of Metastasis
Increasingly, CMC presence is an important target for the prevention of metastasis. The identification of CMCs in patient blood samples during the first year after surgical tumor removal has an 83 % correlation with the recurrence of disease within 8 months of the first detection of CMCs [50] . Additionally, the detection of CMCs in blood samples in the early stages (0-I) of melanoma development is indicative of patients with a high risk of developing metastasis [52] . Adjuvant therapy and additional treatment can then be implemented for those who will most likely be affected by metastasis. Targeting CMCs for personalized therapy using markers found in cells isolated from patients' bloodstreams appears to be a promising means of preventing metastasis (Fig. 3) .
Finally, targeting the genes encoding proteins involved in metastasis development for treatment has the potential to thwart the progression of metastasis. Steps within the EMT, such as the conversion of CDH1 to CDH5, leading to the loss of epithelial intercellular adhesion properties facilitating dermal invasion, intravasation, circulation, and extravasation, could be targeted in CMCs. The retention of cellular junctions would potentially disallow cells from breaking off from the tumor, thereby preventing metastasis [42] . In addition, reduction of IL-8 secretion by invading CMCs could reduce neutrophil-assisted extravasation (Fig. 1 ) by 25-60 %, subsequently reducing metastasis development by *50 % [4] . In addition, many proteins associated with the process of metastasis, including SNA1 (snail and twist), Hedgehog, and Wnt [12] [13] [14] [15] , as well as anti-apoptosis metalloproteins, BCL-2, BCL-XL, and FAK (focal adhesion kinase), could all interfere with metastasis and lead to CMC death before metastasis formation [28, 32, 33] .
Future Directions in the Use and Detection of CMCs
A standardized method of isolation and analysis must be established for those CMCs that have the potential to metastasize. The identification of metastasizing CMCs is clearly necessary for the future development of this research area and the success of targeted therapies (Fig. 3) . Millions of CMCs are sloughed off from tumors daily and enter the bloodstream; however, only very few of these cells are able to survive and establish metastases (Fig. 1 ) [24, 25] . Current CMC methods try to isolate all identifiable CMCs, including those cells that are unable to survive in the bloodstream [34] . Designing a treatment regimen targeting all possible markers found on isolated cells would be far too expensive and possibly toxic because of the number of drugs necessary and possible interactions among these drugs. However, if a marker associated with the ability to survive while circulating or to establish metastatic lesions is identified, only cells expressing this ligand might need to be isolated and targeted, as cells not expressing this factor would not metastasize and would thus be irrelevant. This would be a huge advance in cancer treatment, as it is metastasis that kills patients.
